Expansion Plans Come to Fruition

Charnwood Molecular’s ambitious growth plans have now come to fruition, with the amalgamation of the company’s Loughborough and BioCity laboratories into one, state-of-the-art facility at Charnwood Campus, Loughborough.

The company is now the sole occupier of the substantial 3-storey, laboratory facility. Charnwood Campus is a science, innovation and technology park set in 70 acres of landscaped grounds in Loughborough. The campus was recently designated a ‘Life Sciences Opportunity Zone’, providing an environment to inspire discovery, encourage collaboration and accelerate business growth within the Med-Tech and Biopharma industries.

Charnwood Molecular has seen significant expansion of its global client base in recent years and this latest physical expansion of the business will support its growth plan across a wide range of contract research services: from discovery biology, medicinal chemistry, chemical development and early process research through to developing a suite of complementary services in order to provide a holistic pre-clinical discovery portfolio to its international client base.

CEO of Charnwood Molecular, Steve Allin, commented: “The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories provide substantial capacity for future growth and expansion."

John Handley, Managing Director of Charnwood Molecular, added: “Our expansion plans for the business are now coming to fruition with the move. We are very much looking to the future to make Charnwood Molecular a very major player in the discovery CRO marketplace.”